Scinai Immunotherapeutics Ltd.
SCNI
$2.44
-$0.0734-2.92%
NASDAQ
| 06/30/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 38.28% | -- | -- | -26.11% | -42.02% |
| Total Depreciation and Amortization | 237.41% | -- | -- | 1.38% | 2.99% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 131.82% | -- | -- | -456.57% | 260.94% |
| Change in Net Operating Assets | -115.91% | -- | -- | 265.08% | -545.14% |
| Cash from Operations | 38.87% | -- | -- | 21.53% | -176.83% |
| Capital Expenditure | 98.41% | -- | -- | -1,177.14% | 98.85% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 98.41% | -- | -- | -1,177.14% | 98.85% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -195.12% | -- | -- | 91.46% | 37.60% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 43.14% | -- | -- | 19.85% | -65.69% |